Amgen has raised its bid for Onyx Pharmaceuticals to US$130 per share. Citing a source familiar with the matter, Bloomberg reported that the new bid is presently the highest for…
Amgen boosts Onyx bid to US$130 per share
Would you like to read this article?
Register below to continue reading this article.
You will be able to read 2 articles. No payment details required.
You will also receive our daily M&A insights email.
There is no obligation to subscribe to the service but we hope that after the trialing your firm will decide to subscribe.
For details of subscription packages or if you are considering a subscription and would like to read a few more articles on your trial, please contact us at firstname.lastname@example.org and we will call you to discuss.
Already a subscriber? Login here